Imagine discovering that a cornerstone study you've trusted for years, one that shaped laws and reassured millions about a common chemical, was built on shaky, biased foundations. That's the bombshell shaking the world of pesticides right now, as a major scientific journal pulls back a key paper claiming glyphosate—the active ingredient in Roundup—doesn't cause cancer. But here's where it gets controversial: this retraction hits just as the Trump administration leaps to Bayer's defense in court, fighting to derail lawsuits from cancer patients. Intrigued? Let's dive into the details and unpack why this matters for everyday folks like you and me.
For Immediate Release, December 3, 2025
A Scientific Journal Withdraws Influential Study Asserting No Cancer Link to Glyphosate
This Move Occurs Amid the Trump Administration's Push for the Supreme Court to Halt Cancer Patients' Legal Actions Against Bayer, Glyphosate's Producer
In a surprising turn of events, the journal Regulatory Toxicology and Pharmacology has formally retracted a highly influential research paper on the safety of glyphosate—the primary component in the popular weedkiller Roundup. To clarify for beginners, glyphosate is a chemical widely used in agriculture to kill weeds, and its safety has been a hot topic for years because of concerns about health risks, especially cancer.
The retracted study concluded that glyphosate doesn't pose cancer or other health dangers to humans. However, it was pulled because it depended solely on unpublished data from Monsanto, the original maker of glyphosate (now part of Bayer). Crucially, the researchers didn't examine any independent studies not funded or conducted by Monsanto. On top of that, the journal uncovered evidence suggesting the paper might have been secretly written by Monsanto staff, and it failed to disclose financial ties to the company. This is the part most people miss: in science, transparency is everything—undisclosed funding can skew results, and relying only on industry-sponsored research is like getting advice from someone with a vested interest in the outcome.
To give you a sense of its impact, this paper has been widely referenced by regulatory bodies globally, including the U.S. Environmental Protection Agency (EPA), as proof that glyphosate isn't carcinogenic. In fact, it's among the top 0.1% of most-cited articles on glyphosate in the scientific world, meaning it's cited more than 99.9% of other papers on the topic. For context, imagine a single study influencing decisions that affect farming, food safety, and public health policies—it's that powerful.
“The pesticide industry's long history of twisting science to line its pockets is finally coming to light,” commented Nathan Donley, environmental health science director at the Center for Biological Diversity. “The EPA needs to act fast and reevaluate its stance that glyphosate isn't cancer-causing. Instead of leaning on Monsanto's private research about its own product, they should adopt the independent standards set by the World Health Organization, which classified glyphosate as probably carcinogenic.” This highlights a key controversy: should regulators trust industry-funded science, or is there a conflict of interest that undermines public trust?
And here's the twist—this retraction happens in the same week the Trump administration filed a supportive brief with the U.S. Supreme Court, eagerly backing Bayer's effort to dismiss thousands of lawsuits. These suits allege Bayer knew about glyphosate's cancer risks but didn't warn consumers. Ironically, the class-action victories that Bayer and the government want to overturn revealed emails that served as the main proof for retracting the study. It's like peeling back layers to find the truth hidden beneath.
This stance by the Trump administration starkly contrasts with the Biden administration's 2022 filings, where they urged the Supreme Court not to consider a similar Bayer case. The Court rejected that request back then, but now it's revisiting Bayer's plea.
“Now that so much of the research claiming glyphosate is safe has been discredited, it's absolutely shocking that the Trump administration is rallying for Bayer,” Donley added. “President Trump vowed to shield Americans from harmful chemicals and pesticides, but here they are, fully supporting Bayer's bid to block cancer sufferers from seeking justice. This feels like a huge letdown for the public, putting corporate profits ahead of people's well-being—no ifs, ands, or buts.” This raises eyebrows: Is protecting big business more important than addressing potential public health crises? And what does this say about political priorities when science points in one direction but policies veer another?
This week's retraction echoes a 2018 incident, about seven years ago, when scientists from groups like the Center for Biological Diversity, Center for Food Safety, Pesticide Action Network, and Center for Environmental Health petitioned for a similar withdrawal of a 2016 special issue in Critical Reviews in Toxicology. That issue, entitled “An Independent Review of the Carcinogenic Potential of Glyphosate,” was criticized for being subtly edited and financed by Monsanto, despite its title suggesting neutrality. The journal issued an “Expression of Concern” noting the authors didn't properly reveal Monsanto's involvement, but surprisingly, they didn't retract the papers, even though their own rules call for it. The issue's title still includes “independent review,” which feels misleading given the evidence—emails showed a Monsanto employee heavily revising the manuscript and insisting on harsh language against the World Health Organization's 2015 classification of glyphosate as a probable carcinogen, going against some authors' preferences. Plus, the disclosure falsely claimed no Monsanto review occurred.
For those new to this, it's worth noting why this matters: Independent science means studies free from industry influence, following guidelines like those from the WHO, which help ensure objectivity. Without it, we risk basing policies on biased information, potentially endangering health. As a real-world example, think about how tobacco companies once funded studies downplaying smoking risks—only for the truth to emerge later, leading to major changes in regulations and public awareness.
The Center for Biological Diversity is a nationwide nonprofit with over 1.8 million members and online supporters, focused on safeguarding threatened species and natural habitats.
What do you think? Should governments prioritize corporate interests over public health when science gets messy? Do you agree that industry-funded research can be trusted, or is this a wake-up call for stricter transparency? Share your thoughts in the comments—I'm curious to hear differing views on this heated debate!
